CASI Pharmaceuticals Files 6-K Report
Ticker: CASIF · Form: 6-K · Filed: Sep 2, 2025 · CIK: 1962738
Sentiment: neutral
Topics: reporting, foreign-private-issuer, sec-filing
TL;DR
CASI Pharma filed a 6-K, incorporating docs into F-3. Standard reporting.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on September 2, 2025, for the month of September 2025. This filing is a report of a foreign private issuer and incorporates by reference information from Exhibits 99.1 into the Company's Registration Statements on Form F-3 (File No. 333-28399). The company's principal executive office is located in Beijing, People's Republic of China.
Why It Matters
This filing indicates ongoing reporting requirements for CASI Pharmaceuticals, Inc. as a foreign private issuer, potentially affecting investor awareness of its regulatory status and disclosures.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not appear to contain significant new financial or operational information.
Key Numbers
- 001-41666 — SEC File Number (Identifies CASI Pharmaceuticals, Inc. in SEC filings.)
- 333-28399 — Form F-3 File Number (References the company's registration statements.)
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer of the 6-K report
- 001-41666 (company) — SEC File Number for CASI Pharmaceuticals, Inc.
- 333-28399 (company) — File number for CASI Pharmaceuticals, Inc.'s Form F-3 Registration Statements
- September 2, 2025 (date) — Filing date of the 6-K report
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, typically to provide information that the issuer makes or is required to make public pursuant to the laws of its home country or that it furnishes or is required to furnish to its security holders.
What does it mean that information is incorporated by reference into Form F-3 Registration Statements?
Incorporation by reference means that the information contained in the 6-K filing is legally considered part of the company's F-3 Registration Statements, making it available to investors and regulators as if it were directly included in those statements.
Where is CASI Pharmaceuticals, Inc. headquartered?
CASI Pharmaceuticals, Inc.'s principal executive office is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, People's Republic of China.
What is the SIC code for CASI Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for CASI Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Has CASI Pharmaceuticals, Inc. changed its name previously?
Yes, the company was formerly known as CASI Pharmaceuticals Holdings, Inc., and the name change occurred on January 18, 2023.
Filing Stats: 234 words · 1 min read · ~1 pages · Grade level 10.9 · Accepted 2025-09-02 09:15:25
Filing Documents
- tm2522428d2_6k.htm (6-K) — 11KB
- tm2522428d2_ex99-1.htm (EX-99.1) — 15KB
- tm2522428d2_ex99-1img001.jpg (GRAPHIC) — 16KB
- 0001104659-25-086101.txt ( ) — 50KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ David Cory Name: David Cory Title: CEO Date: September 2, 2025